Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
April 26, 2022 17:19 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm with...
Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting
April 12, 2022 13:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., April 12, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference
March 29, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., March 29, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update
March 24, 2022 08:00 ET
|
Gain Therapeutics, Inc.
$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company’s lead program into clinical trials ---Compelling...
Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference
March 15, 2022 08:00 ET
|
Gain Therapeutics, Inc.
Study results provide additional validation that SEE-Tx platform identifies brain-penetrant small molecules ideally suited for CNS diseases caused by protein misfolding Demonstration of in vitro and...
Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences
March 01, 2022 08:00 ET
|
Gain Therapeutics, Inc.
- Oppenheimer 32nd Annual Healthcare Conference - - AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders - - Krabbe Translational...
Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022
February 08, 2022 08:00 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day
February 04, 2022 12:06 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming and accelerating drug discovery with...
Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day
January 31, 2022 16:05 ET
|
Gain Therapeutics, Inc.
BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted...
Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences
January 18, 2022 08:00 ET
|
Gain Therapeutics, Inc.
- Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable -- 18th Annual WORLDSymposium –- AD/PD™ 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE...